Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1215 Neoplasms 1024 Carcinoma, Non-Small-Cell Lung 747 Prostatic Neoplasms 687 Colorectal Neoplasms 590 Lung Neoplasms 572 Pancreatic Neoplasms 394 Leukemia, Myeloid, Acute 394 Neoplasm Metastasis 387 Ovarian Neoplasms 370 Multiple Myeloma 369 Stomach Neoplasms 316 Carcinoma, Hepatocellular 301 Melanoma 281 Brain Neoplasms 277 Recurrence 273 Squamous Cell Carcinoma of Head and Neck 267 Head and Neck Neoplasms 237 Endometrial Neoplasms 234 Glioblastoma 233 Triple Negative Breast Neoplasms 228 Uterine Cervical Neoplasms 221 Precursor Cell Lymphoblastic Leukemia-Lymphoma 221 Lymphoma 221 Sarcoma 201 Hematologic Neoplasms 199 Urinary Bladder Neoplasms 196 Esophageal Neoplasms 190 Carcinoma, Renal Cell 187 Lymphoma, Non-Hodgkin 175

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Low Grade Serous Ovarian Cancer × 1 year × Clear all

NCT06072781 2026-04-02

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡